Immune

Thymosin Alpha-1

Mechanism

A 28-amino-acid peptide hormone. Modulates T-cell function, dendritic cell activity, and Th1/Th2 balance. Approved as a pharmaceutical (Zadaxin) in 35+ countries for chronic hepatitis B/C, immune deficiency, and cancer adjunct therapy.

Typical dose

1.6mg subcutaneous twice weekly (clinical). 800mcg-1.6mg per injection, 2-3 times weekly (research).

Cycle length

12-24 weeks; pulsed cycling per protocol

Form

Injectable (subcutaneous)

Deep dives on Thymosin Alpha-1

6 Best Peptides for Anti-Ageing and Longevity (2026)The anti-ageing peptide consensus is wrong. We rank epitalon, MOTS-c, and GHK-Cu by what the primary literature actually proves vs what marketing narratives claim.
BPC-157 and TB-500 Post-Surgery Recovery Protocol: When to Start, Dosing, and Cycle Length (2026)BPC-157 and TB-500 post-surgery recovery: when to start, dosing, cycle length, and what the evidence supports for accelerated soft-tissue healing.
What the FDA Reclassification Actually Means for Peptide UsersFDA peptide reclassification 2026: what Category 2 to Category 1 actually means for users, what's changed, what hasn't, and what to expect from the July PCAC meeting.
Thymosin Alpha-1 Complete Guide: The Immune-Modulating Peptide With 35-Country Approval (2026)Thymosin alpha-1 complete guide: mechanism, dosing protocols, cycling, sourcing, and the clinical evidence behind the most validated immune peptide.
7 Best Peptides for Injury Recovery (2026 Guide)The 7 best peptides for injury recovery ranked by evidence and practical use. Covers BPC-157, TB-500, the Wolverine Stack, GHK-Cu, CJC-1295/Ipamorelin, Thymosin Alpha-1, and KPV with protocols and stacking guidance.

Get the Pre-Protocol Checklist

Free checklist plus weekly protocols, research breakdowns, and tactical guides. No spam. Unsubscribe anytime.